Review of NICE Technology Appraisal Guidance No.284; Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced and/or metastatic ovarian cancer, and No.285; Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Proposal to move the existing guidance to the static list – April 2016
The planned date for the review of TA284 is April 2016, and the planned date for the review of TA285 is June 2016.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
There is no new evidence available that is likely to change the existing recommendations made in TA284 or TA285.
Consequently we propose that both TA284 and TA285 should move to the ‘static list’ of technology appraisals.
Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.
Please see appendix A for a full list of the organisations we have contacted.
This page was last updated: 25 April 2016